Bio-Rad Laboratories (NYSE:BIO) Posts Earnings Results, Misses Expectations By $0.08 EPS

by · The Cerbat Gem

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) released its earnings results on Thursday. The medical research company reported $1.89 EPS for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08), FiscalAI reports. The business had revenue of $592.10 million for the quarter, compared to the consensus estimate of $589.89 million. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The company’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.54 earnings per share.

Here are the key takeaways from Bio-Rad Laboratories’ conference call:

  • Updated 2026 guidance tightened: the company now expects currency‑neutral revenue growth of -3% to +0.5%, full‑year non‑GAAP gross margin of 53–54% and operating margin of 10–12%, citing a ~$11M Q1 impact and an ongoing headwind from the Middle East conflict that could materially pressure revenue and margins for 2026.
  • Digital PCR momentum: ddPCR instrument revenue grew 24% in Q1, the new QX700 has >99% of assays enabled ahead of plan, and the Stilla acquisition is on track to be accretive by mid‑year, supporting future consumables pull‑through and share gains.
  • Accounting volatility: reported net loss of $527M was driven by a $562M fair‑value decline in the company’s Sartorius equity stake, while non‑GAAP net income was $51M ($1.89 EPS), separating market valuation swings from core operating results.
  • Operational efficiency initiatives include manufacturing select life‑science instruments In China for China, procurement and manufacturing rationalization, and R&D reprioritization toward higher‑return areas (digital PCR, oncology assays and embedded AI) to improve agility and margins.
  • Balance sheet and capital allocation: Q1 free cash flow was $78M, cash and short‑term investments were $1.565B, the company repurchased ~$48M of stock in the quarter and has ~$237M remaining under its buyback authorization.

Bio-Rad Laboratories Stock Performance

BIO traded up $4.50 during trading hours on Thursday, hitting $279.65. The stock had a trading volume of 650,153 shares, compared to its average volume of 246,573. The company’s fifty day simple moving average is $277.81 and its 200 day simple moving average is $298.20. Bio-Rad Laboratories has a 1 year low of $211.43 and a 1 year high of $343.12. The stock has a market cap of $7.55 billion, a PE ratio of 10.02 and a beta of 1.16. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several large investors have recently added to or reduced their stakes in BIO. Geneos Wealth Management Inc. increased its holdings in Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Bio-Rad Laboratories during the 4th quarter valued at about $47,000. Itau Unibanco Holding S.A. grew its holdings in Bio-Rad Laboratories by 57.6% during the 4th quarter. Itau Unibanco Holding S.A. now owns 197 shares of the medical research company’s stock valued at $60,000 after buying an additional 72 shares in the last quarter. State of Wyoming purchased a new position in Bio-Rad Laboratories during the 4th quarter valued at about $74,000. Finally, Quarry LP grew its holdings in Bio-Rad Laboratories by 131.5% during the 3rd quarter. Quarry LP now owns 287 shares of the medical research company’s stock valued at $80,000 after buying an additional 163 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on BIO. Citigroup cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $375.00 to $300.00 in a research note on Tuesday, April 7th. Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Bio-Rad Laboratories presently has a consensus rating of “Hold” and an average price target of $339.75.

View Our Latest Analysis on Bio-Rad Laboratories

Bio-Rad Laboratories Company Profile

(Get Free Report)

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.

Featured Stories